David P. Schenkein - Nov 11, 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Director
Signature
/s/ Tyler Nielsen, by power of attorney
Stock symbol
DNLI
Transactions as of
Nov 11, 2024
Transactions value $
-$1,083,695
Form type
4
Date filed
11/13/2024, 04:18 PM
Previous filing
Jun 24, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Options Exercise $849K +47.2K +219.41% $18.00 68.7K Nov 11, 2024 Direct F1
transaction DNLI Common Stock Sale -$871K -27.1K -39.51% $32.09 41.5K Nov 11, 2024 Direct F1, F2, F3
transaction DNLI Common Stock Sale -$1.06M -32.3K -77.8% $32.87 9.22K Nov 11, 2024 Direct F1, F2, F4
holding DNLI Common Stock 26.2K Nov 11, 2024 See footnote F5
holding DNLI Common Stock 31.2K Nov 11, 2024 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DNLI Stock Option (right to buy) Options Exercise $0 -47.2K -100% $0.00 0 Nov 11, 2024 Common Stock 47.2K $18.00 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 5,967 Unvested RSUs.
F2 The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted August 12, 2024.
F3 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $31.54 to $32.53 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $32.54 to $33.28 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 The shares are held of record by the David P. Schenkein 2004 Revocable Trust, for which the Reporting Person serves as a trustee.
F6 The shares are held of record by the Amy P. Schenkein 2004 Revocable Trust, for which the Reporting Person's spouse serves as a trustee.
F7 25% of the shares subject to the option shall vest on December 7, 2018 and an additional 1/48 of the shares vest monthly thereafter.